Compare Abeona Therapeutics Inc (ABEO) vs Invesco DB Oil Fund (DBO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Invesco DB Oil Fund — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Invesco DB Oil Fund trades at $18.79. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Invesco DB Oil Fund nearer its low. Which is the better fit depends on your goals.
| ABEO | DBO | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Commodities - Energy |
52-Week High | $7.23 | $23.80 |
52-Week Low | $4.17 | $11.98 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
DBO trades at $17.34 with a modest 0.35% daily gain amid bearish technical signals. The stock shows mixed momentum with oversold RSI readings but faces strong resistance at $18. Recent oil price volatility driven by Middle East tensions and supply disruptions creates both opportunities and risks for energy sector stocks.
The outlook remains cautious with technical indicators favoring bearish momentum, though oversold conditions suggest potential for near-term stabilization. Investment opportunity exists if geopolitical tensions sustain higher oil prices, but risks include supply growth and demand uncertainty that could pressure energy stocks further.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →
